Literature DB >> 16446314

Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma.

I H van Veen1, P J Sterk, R Schot, S A Gauw, K F Rabe, E H Bel.   

Abstract

Alveolar nitric oxide (NO) is a measure of peripheral airway inflammation in asthma, potentially associated with disease severity. The relationship between alveolar NO and physiological tests of peripheral airway (dys)function has not been investigated. The present authors hypothesised that peripheral airway inflammation and dysfunction are inter-related and associated with asthma severity. Alveolar NO was compared between 17 patients with mild-to-moderate asthma and 14 patients with severe asthma and related to total lung capacity (TLC), residual volume (RV)/TLC, thoracic gas volume (FRC), slope of the single breath nitrogen washout curve (dN2), closing capacity (CC)/TLC and fall in forced vital capacity at the provocative concentration of methacholine causing a 20% fall in forced expiratory volume in one second. In patients with severe asthma, strong correlations were found between alveolar NO and RV/TLC % pred, FRC % pred, dN2, and CC/TLC. Patients with oral steroid-dependent asthma had higher alveolar NO levels (2.7 ppb) compared with the other patients with severe (0.6 ppb) and mild-to-moderate asthma (0.3 ppb). The present authors conclude that alveolar nitric oxide is closely related to parameters of peripheral airway dysfunction in patients with severe asthma, and that oral steroid-dependent asthmatics have more peripheral airway disease than nonsteroid-dependent asthmatics. This suggests that patients on chronic oral steroid treatment have more extensive disease and require additional anti-inflammatory treatment to better target the peripheral airways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446314     DOI: 10.1183/09031936.06.00087905

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  27 in total

1.  Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD.

Authors:  Peter A Williamson; Karine Clearie; Daniel Menzies; Sriram Vaidyanathan; Brian J Lipworth
Journal:  Lung       Date:  2010-12-22       Impact factor: 2.584

Review 2.  Small airways disease in asthma.

Authors:  Jonathan Corren
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

3.  Extrafine HFA-beclomethasone dipropionate versus budesonide for asthma: a meta-analysis.

Authors:  Xin Chen; Yingbo Kang; Liqing Wang; Lin Lin; Zhe Zhu; Rui Chen
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis: a pilot feasibility study.

Authors:  J Choi; L A Hoffman; J M Sethi; T G Zullo; K F Gibson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

5.  Elevated Levels of Alveolar Nitric Oxide May Indicate Presence of Small Airway Inflammation in Patients with Inflammatory Bowel Disease.

Authors:  Adonis A Protopapas; Stergios Vradelis; Theodoros Karampitsakos; Paschalis Steiropoulos; Athanasios Chatzimichael; Emmanouil Paraskakis
Journal:  Lung       Date:  2019-07-17       Impact factor: 2.584

6.  FeNO as a Marker of Airways Inflammation: The Possible Implications in Childhood Asthma Management.

Authors:  Marcello Verini; Nicola Pietro Consilvio; Sabrina Di Pillo; Anna Cingolani; Cynzia Spagnuolo; Daniele Rapino; Alessandra Scaparrotta; Francesco Chiarelli
Journal:  J Allergy (Cairo)       Date:  2010-05-18

Review 7.  Severe asthma: what makes it so hard to manage?

Authors:  Luke Carlstrom; Mario Castro
Journal:  Curr Allergy Asthma Rep       Date:  2009-09       Impact factor: 4.806

Review 8.  Partitioned exhaled nitric oxide to non-invasively assess asthma.

Authors:  James L Puckett; Steven C George
Journal:  Respir Physiol Neurobiol       Date:  2008-07-31       Impact factor: 1.931

9.  Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy.

Authors:  Peter A Williamson; Philip M Short; Sriram Vaidyanathan; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

10.  Effect of fluticasone 250 microg/salmeterol 50 microg and montelukast on exhaled nitric oxide in asthmatic patients.

Authors:  Arthur F Gelb; Colleen Flynn Taylor; Chris M Shinar; Carlos A Gutierrez; Noe Zamel
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.